# Tesamorelin trial results

> Tesamorelin fat results | Ascending Peptides — Ascending Peptides examines tesamorelin’s visceral-fat and liver-fat findings in adults with HIV, its limited approval and the safety questions that remain.

Here the experiment reaches beyond the blood test. I give the fat measurements considerable weight, with the patients and the units attached.

## The fat measured in adults with HIV

Tesamorelin stimulates growth-hormone release through a copy of growth hormone-releasing hormone. Its [US approval in 2010](https://www.ncbi.nlm.nih.gov/books/NBK548730/) concerns reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. That is a particular disorder of fat distribution. General weight loss and anti-aging remain outside the approved use.

The trials go further than showing a hormonal response. In the [26-week study of 412 people with HIV and abdominal fat accumulation](https://pubmed.ncbi.nlm.nih.gov/18057338/), researchers measured a reduction in visceral fat, the fat surrounding internal abdominal organs. Hormones and blood fats changed too. For that specific fat outcome, I trust the tissue measurement more than the CJC-1295 hormone readings.

## What the scan’s area means

A [six-month trial in fifty adults with HIV](https://pubmed.ncbi.nlm.nih.gov/25038357/) measured visceral and liver fat. The treatment effect on visceral fat was a reduction of 42 square centimeters compared with placebo. The unit matters: this is fat area on a scan, rather than a mass that can be converted into pounds lost. Liver fat decreased too.

An abdominal teaching model helps locate the compartment at issue, although the model cannot show a trial’s result. The measured change belongs to the scans of the people studied. My confidence concerns the measured compartment change in these adults. A relevant trial would have to establish the result for another cause of weight gain.

![Open anatomical abdomen model showing organs and surrounding fat](images/tesamorelin-abdominal-model.webp)

*Illustrative teaching model locating abdominal organs and surrounding fat. It represents no participant, scan or treatment result.*

## Several trials, a specific population

The [2026 meta-analysis of five randomized trials](https://pubmed.ncbi.nlm.nih.gov/41545261/) brought together evidence in HIV-associated lipodystrophy. It found reductions in visceral, trunk and liver fat, alongside increased lean body mass. Lean body mass includes water as well as muscle, so that result alone cannot establish increased muscle tissue.

Pooling the studies gives a broader account of the same clinical setting. It still leaves the difference between HIV-associated fat redistribution and ordinary weight gain intact. The evidence interests me more when that boundary is stated clearly: there is a real measured effect here, with a defined reach.

## Visceral fat through week 52

In the [52-week program](https://pubmed.ncbi.nlm.nih.gov/18690162/), visceral fat remained 18% below baseline during continued tesamorelin treatment. Fat reaccumulated after treatment stopped. That follow-up describes the durability available in the experiment, rather than a permanent change established by the initial loss.

The reaccumulating fat tempers my enthusiasm about durability. A useful effect can depend on continued treatment, and that dependence makes later safety and the burden of treatment more consequential. The follow-up belongs beside the initial fat reduction whenever the result is discussed.

## Glucose findings and longer cancer follow-up

In a separate [two-week study of thirteen healthy men](https://pubmed.ncbi.nlm.nih.gov/20943777/), tesamorelin raised overnight growth hormone and IGF-1, while fasting glucose and insulin-stimulated glucose uptake showed no significant change. Those findings offer reassurance for those measurements over that short interval. They do not settle glucose effects during years of treatment or in every population.

Tesamorelin raises a growth factor, and the current evidence leaves longer-term cancer safety incompletely answered. The cited trials did not establish an excess of cancer attributable to treatment; that observation cannot guarantee safety over a longer period. The [sports-medicine review](https://pubmed.ncbi.nlm.nih.gov/42160466/) adds concerns about unregulated material and anti-doping restrictions. Tesamorelin is prohibited in sport.

Of these three compounds, tesamorelin has the clearest demonstrated human tissue outcome for its specified condition. I credit that measured benefit within its defined population. The [comparison](/compare) shows why the other hormone responses cannot simply inherit it.

---

An independent reading of the growth-hormone signal as it ascends from receptor to evidence—an editorial digest, never a storefront or medical instruction.